- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
Enrollment change, Trial withdrawal, Combination therapy, Metastases: CBT-1 (clinicaltrials.gov) - Jun 20, 2017 P1, N=0, Withdrawn, Trial primary completion date: Aug 2018 --> Aug 2019 N=46 --> 0 | Suspended --> Withdrawn
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. (Pubmed Central) - Jun 18, 2017 Trial primary completion date: Apr 2017 --> Apr 2018 Neither doxorubicin nor mitomycin C potentiated the cytotoxic effects of ischemia...Conclusion Ischemia induces quiescence in surviving HCC cells, resulting in a dependence on autophagy, providing a potential therapeutic target for combination therapy with TAE.
- |||||||||| Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial primary completion date: ALL Adult Consortium Trial: Adult ALL Trial (clinicaltrials.gov) - Jun 16, 2017 P2, N=112, Active, not recruiting, Neither doxorubicin nor mitomycin C potentiated the cytotoxic effects of ischemia...Conclusion Ischemia induces quiescence in surviving HCC cells, resulting in a dependence on autophagy, providing a potential therapeutic target for combination therapy with TAE. Trial primary completion date: Jun 2016 --> Jul 2017
- |||||||||| Oncaspar liquid (pegaspargase) / Servier
Clinical: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Jun 14, 2017 P3, N=800, Active, not recruiting, A prospective trial to validate this concept is warranted. Trial primary completion date: Jun 2015 --> Aug 2014
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Trial primary completion date: Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients (clinicaltrials.gov) - Jun 14, 2017 P3, N=482, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2019 --> Jun 2017
- |||||||||| Trial initiation date, Trial primary completion date: Vaccination of Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Jun 14, 2017
P2, N=102, Not yet recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2019 --> Jun 2017 Initiation date: Oct 2016 --> Oct 2017 | Trial primary completion date: Nov 2019 --> Nov 2020
- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
Trial suspension, Combination therapy, Metastases: CBT-1 (clinicaltrials.gov) - Jun 9, 2017 P1, N=46, Suspended, Trial primary completion date: Mar 2017 --> Mar 2018 Not yet recruiting --> Suspended
- |||||||||| cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg., vinblastine / Generic mfg.
Enrollment change, Trial initiation date, Trial termination: SWOG-4B951: 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer (clinicaltrials.gov) - Jun 8, 2017 P3, N=521, Terminated, With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT. N=800 --> 521 | Initiation date: Sep 1998 --> Aug 1997 | Active, not recruiting --> Terminated; Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis.
- |||||||||| Adcetris (brentuximab vedotin) / Seagen, Takeda, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: How I manage patients with grey zone lymphoma. (Pubmed Central) - Jun 4, 2017 For patients with relapsed/refractory GZL, salvage chemotherapy followed by consolidative autologous HSCT should be considered. Finally, continued biological and pathologic examination of this unique disease entity is warranted as well as exploration towards the integration of targeted therapeutic agents (e.g., brentuximab vedotin, programmed cell death 1inhibitors, B-cell receptor inhibitors, proteasome inhibitors, etc.) into the treatment paradigm of GZL.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Tumor stroma interaction is mediated by monocarboxylate metabolism. (Pubmed Central) - Jun 1, 2017 Finally, we found that inhibiting or interfering with ROS management, using the naturally occurring flavonoid phloretin (found in apple tree leaves), adds to the cytotoxicity of the conventional chemotherapeutic agent doxorubicin. Our work demonstrates that a lactate-pyruvate, reciprocally-supportive metabolic relationship may be operative within the tumor microenvironment (TME) to support tumor growth, and may be a useful drug target.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed, Trial initiation date, Trial primary completion date, Combination therapy: CAVALLI: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (clinicaltrials.gov) - May 31, 2017 P1/2, N=267, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Initiation date: Jun 2014 --> Nov 2013 | Trial primary completion date: Aug 2019 --> Aug 2017
- |||||||||| Oncaspar liquid (pegaspargase) / Servier
Clinical: Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL (clinicaltrials.gov) - May 30, 2017 P2/3, N=660, Recruiting, Recruiting --> Active, not recruiting | Initiation date: Jun 2014 --> Nov 2013 | Trial primary completion date: Aug 2019 --> Aug 2017 Trial primary completion date: Sep 2016 --> Sep 2018
- |||||||||| Review, Journal: Chemotherapy for soft tissue sarcoma. (Pubmed Central) - May 27, 2017
Despite 2 recent drug approvals, doxorubicin and ifosfamide remain the most effective chemotherapy drugs available for the treatment of majority of these tumors...Fixed-dose-rate gemcitabine with or without docetaxel is a standard second-line treatment...Eribulin has recently been approved on the basis of improved overall survival for patients with adipocytic sarcomas, and trabectedin is now approved in the United States for patients with leiomyosarcoma and liposarcoma. Within the spectrum of targeted therapies, pazopanib is approved for all nonadipocytic sarcomas, and imatinib is approved for dermatofibrosarcoma protuberans...Cancer 2016.
- |||||||||| Enrollment change: Combination Chemotherapy in Treating Patients With Sarcoma (clinicaltrials.gov) - May 25, 2017
P=N/A, N=28, Completed, Within the spectrum of targeted therapies, pazopanib is approved for all nonadipocytic sarcomas, and imatinib is approved for dermatofibrosarcoma protuberans...Cancer 2016. N=120 --> 28
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, bendamustine / Generic mfg.
Journal: RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. (Pubmed Central) - May 24, 2017 The Southwestern Oncology Group S1106 trial was designed to assess rituximab plus hyperCVAD/MTX/ARAC (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate) (RH) versus rituximab plus bendamustine (RB) in a randomized phase II trial to select a pre-transplant induction regimen for future development...Premature closure of the study limited the sample size and the precision of PFS estimates and MRD rates. However, RB can achieve a deep remission and could be a platform for future trials in MCL.
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date: BrUOG 308: Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. (clinicaltrials.gov) - May 24, 2017 P2, N=30, Recruiting, However, RB can achieve a deep remission and could be a platform for future trials in MCL. Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Nov 2016
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Double Hit Lymphoma: From Biology to Therapeutic Implications. (Pubmed Central) - May 20, 2017 These DEL cases, which represent a significant proportion of newly diagnosed DLBCL, have a poor outcome with R-CHOP and there is little consensus on how they should be approached. This review will focus on the biology and treatment of DHL and DEL, discuss the outcome of these diseases with current standard as well as promising new approaches and conclude with a section on novel agents that are in development for these diseases.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Copper-64 labeled liposomes for imaging bone marrow. (Pubmed Central) - May 18, 2017 SHL patients appear to have a poor prognosis, which may be improved with receipt of intensive induction. Our results indicate that our novel PET labeled liposomes target bone marrow with very high efficiency and therefore can function as efficient bone marrow imaging agents.
|